[Therapeutic options for mineral metabolism disorders in dialysis patients: a case report].
Mineral metabolism disorders are well-recognized complications in patients with chronic kidney disease (CKD). Furthermore, hyperphosphatemia and secondary hyperparathyroidism are associated with both renal osteodystrophy and cardiovascular disease. During the last 5 years, new therapeutic options have become available to treat these conditions in CKD. We describe the case of a 70-year-old lady with a dialysis history of 5 years and a number of cardiovascular risk factors (hypertension, hypercholesterolemia and obesity). Unfortunately, the patient was poorly compliant with any pharmaceutical treatment. After 2 years, a pharmacological approach with a low dosage of calcium salts and sevelamer HCl, subsequently changed to lanthanum carbonate, intravenous paricalcitol, and cinacalcet HCl reached the goals suggested by the current guidelines. Every nephrologist should look at the pathogenesis and treatment of hyperphosphatemia and secondary hyperparathyroidism. New options are now available and may help the clinician to obtain satisfactory short- and long-term outcomes in the treatment of this disease.
Cozzolino
M
M
Unita' Operativa Nefrologia e Dialisi, Azienda Ospedaliera 'San Paolo', Cattedra di Nefrologia, Universita' degli Studi, Milano - Italy. mariocozzolino@hotmail.com
Pasho
S
S
Missaglia
E
E
Crovetto
C
C
Fallabrino
G
G
Brancaccio
D
D
D000368:Aged; D002128:Calcium Metabolism Disorders / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D006961:Hyperparathyroidism / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D010760:Phosphorus Metabolism Disorders / Q000188:drug therapy* / Q000209:etiology; D006435:Renal Dialysis